NASDAQ Stocks
· Apr 26, 2025 2:10 PM EDT
Not market news
Protara Therapeutics Reports Promising Phase 2 Results for TARA-002 in Non-Muscle Invasive Bladder Cancer
TARA-002 shows promising efficacy in NMIBC patients, with favorable safety and upcoming interim data presentation scheduled for 2025.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
